Francesca Micci

Dr. Francesca Micci


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
FMFrancesca Micci
Francesca Micci
IPIoannis Panagopoulos
Ioannis Panagopoulos
BBBodil Bjerkehagen
Bodil Bjerkehagen
SHSverre Heim
Sverre Heim
Endometrial stromal sarcomas (ESS) represent <10% of all uterine sarcomas. Cytogenetic data on this tumor type are limited to 32 cases, and the karyotypes are often complex, but the pattern of rearrangement is nevertheless clearly nonrandom with particularly frequent involvement of chromosome arms 6p and 7p. Recently, a specific translocation t(7;17)(p15;q21) leading to the fusion of two zinc finger genes, juxtaposed with another zinc finger (JAZF1) and joined to JAZF1 (JJAZ1), was described in a subset of ESS. We present three ESS whose karyotypes were without the disease-specific t(7;17) but instead showed rearrangement of chromosomal band 6p21, twice as an unbalanced t(6p;7p) and once as a three-way 6;10;10 translocation. All three tumors showed specific rearrangement of the PHD finger protein 1 (PHF1) gene, located in chromosomal band 6p21. In the two tumors with t(6;7), PHF1 was recombined with the JAZF1 gene from 7p15, leading to the formation of a JAZF1/PHF1 fusion gene. The third tumor showed a t(6p;10q;10p) as the sole karyotypic abnormality, leading to the fusion of PHF1 with another partner, the enhancer of polycomb (EPC1) gene from 10p11; EPC1 has hitherto not been associated with neoplasia. The PHF1 gene encodes a protein with two zinc finger motifs whose involvement in tumorigenesis and/or tumor progression has not been reported before, but its rearrangement clearly defines a new pathogenetic subgroup of ESS. (Cancer Res 2006; 66(1): 107-12)

1 May 2014 in Cancer Letters
Verified
Journal Article
Closed access
FMFrancesca Micci
Francesca Micci
LGLudmila Gorunova
Ludmila Gorunova
SGSonia Gatius
Sonia Gatius
XMXavier Matias-Guiu
Xavier Matias-Guiu
BDBen Davidson
Ben Davidson
IPIoannis Panagopoulos
Ioannis Panagopoulos

24 May 2016 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
PDF file
FMFrancesca Micci
Francesca Micci
LGLudmila Gorunova
Ludmila Gorunova
AAAntonio Agostini
Antonio Agostini
LJLene E. Johannessen
Lene E. Johannessen
MBMarta Brunetti
Marta Brunetti
IPIoannis Panagopoulos
Ioannis Panagopoulos
Recent cytogenetic and molecular investigations have improved our understanding of endometrial stromal tumors, including sarcomas (ESS), and helped redefine their classification into more pathogenetically meaningful categories. Because much more can be gained through such studies, we add information on another 22 ESS examined by karyotyping, PCR analysis, expression array analysis, and transcriptome sequencing. In spite of the known preference for certain pathogenetic pathways, we found considerable genetic heterogeneity in high‐grade (HG) as well as in low‐grade (LG) ESS. Not all HG tumors showed a YWHAE‐NUTM chimeric transcript and as many as six LGESS showed no hitherto known ESS‐related fusions. Among the transcripts identified by transcriptome sequencing and verified by Sanger sequencing, new variants of ZC3H7‐BCOR and its reciprocal BCOR‐ZC3H7 were identified as was involvement of the CREBBP and MLLT4 genes (both well known leukemia‐related genes) in two new fusions. FISH analysis identified a known EPC1‐PHF1 fusion which led to the identification of a new variant at the molecular level. The fact that around 70 genes were found differentially expressed, by microarray analysis, when comparing LGESS showing ESS‐related fusions with LGESS without such transcripts, underscores the biochemical importance of the observed genetic heterogeneity and hints that new subgroups/entities in LGESS still remain undiscovered. © 2016 The Authors. Genes, Chromosomes & Cancer Published by Wiley Periodicals, Inc.

11 September 2012 in Leukemia
Verified
Journal Article
Open access
FMFrancesca Micci
Francesca Micci
JTJ Thorsen
J Thorsen
IPI Panagopoulos
I Panagopoulos
KNK B Nyquist
K B Nyquist
BZB Zeller
B Zeller
SHS Heim
S Heim
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.

6 September 2017 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
PDF file
FMFrancesca Micci
Francesca Micci
MBMarta Brunetti
Marta Brunetti
PCPaola Dal Cin
Paola Dal Cin
MNMarisa R. Nucci
Marisa R. Nucci
LGLudmila Gorunova
Ludmila Gorunova
IPIoannis Panagopoulos
Ioannis Panagopoulos
We present a new endometrial stromal sarcoma (ESS)‐associated genomic rearrangement involving chromosome arms 5p and 6p and leading to the formation of a BRD8‐PHF1 fusion gene. The PHF1 (PHD finger protein 1) gene, from 6p21, is known to be rearranged in ESS in a promiscuous way inasmuch as it has been shown to recombine with JAZF1, EPC1, MEAF6, and now also with BRD8, in tumors of this type. In all rearrangements of PHF1, including the present one, a recurrent theme is that the entire coding part of PHF1 constitutes the 3′ end of the fusion. BRD8 (bromodomain containing 8) encodes a protein which is involved in regulation of protein acetylation and/or histone acetyl transferase activity. All the genetic fusions identified so far in ESS appear to recombine genes involved in transcriptional regulation, that is, polycomb group complex‐mediated and aberrant methylation/acetylation genes. This adds to the likelihood that the new BRD8‐PHF1 shares the same pathogenetic mechanism as the other ESS‐specific rearrangements.

24 October 2020 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
PDF file
FMFrancesca Micci
Francesca Micci
SHSverre Heim
Sverre Heim
IPIoannis Panagopoulos
Ioannis Panagopoulos
Endometrial stromal sarcomas (ESS) are a heterogeneous group of rare mesenchymal cancers. Considerable knowledge has been gained in recent years about the molecular characteristics of these cancers, which helps to classify them in a more meaningful manner leading to improved diagnosis, prognostication, and treatment. According to this classification, ESS is now grouped as low‐ or high‐grade. ESS may have overlapping clinical presentation, morphology, and immunohistochemical profile. Their genetic characteristics allow subdivision of many of them depending on which pathogenetically important fusion genes they carry, but clearly much more needs to be unraveled in this regard. We here provide an overview of the molecular pathogenetic knowledge gained so far on low‐ and high‐grade ESS.